Executive Management

Brad is the founder of GlyTherix. He has a PhD in protein chemistry, led research groups in government agencies, universities and hospitals and founded three companies. He was a joint recipient of the 2015 Eureka Prize, for Interdisciplinary Research. He has co-authored over 100 peer-reviewed papers and book chapters and seven patents.

A seasoned financial professional having worked in chemical, telecommunications and financial services industries. He has held various senior/board positions, for listed and unlisted companies, in Australia, UK and Hong Kong, including GFA International Limited, Swire Blanch Limited and OAMPS Limited.

Douglas is the Head of Research and Development and leads the scientific team. He has 20 years of experience in biomedical research with a particular focus on drug development and oncology. Most recently, he was involved in the development of a novel antibody (MDX-1097) from pre-clinical to Phase 2 clinical trials.

Yanling is a technical leader with over 18 years of experience in biologics and medical device development and manufacturing. She was involved in developing two commercial antibody products working with Cambridge Antibody Technology and UCB-CellTech. She was a Senior Scientist in Bioprocess Development at Medimmune leading key CMC programs. Yanling is conversant with quality and regulatory requirements.